APGE Apogee Therapeutics, Inc.

OTO
$134.55

Apogee Therapeutics, Inc. (APGE) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $1.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.0% since its last earnings release on August 10, 2026.

Apogee Therapeutics, Inc. Missed Consensus Estimates
Monday, August 10, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($1.14)
Rev est $100M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $134.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Apogee Therapeutics, Inc.

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow